ID8 cell lysate-pulsed dendritic cell vaccine

The ID8 cell lysate-pulsed dendritic cell vaccine is an experimental autologous cell-based immunotherapy primarily utilized in preclinical models of ovarian cancer. The vaccine is produced by harvesting dendritic cells (DCs)—typically bone marrow-derived in murine models—and pulsing them *in vitro* with a whole-cell lysate derived from the ID8 mouse ovarian cancer cell line. The lysate, which contains a broad spectrum of tumor-associated antigens (TAAs) such as Sperm Protein 17 (SP17), is often prepared using freeze-thaw cycles or chemical oxidation (e.g., with hypochlorous acid) to enhance immunogenicity. Once the DCs are loaded with these antigens and matured using stimuli like LPS and IFN-γ, they are administered back into the host via intradermal, subcutaneous, or intraperitoneal routes. The mechanism of action involves the DCs migrating to secondary lymphoid organs where they present the tumor antigens to T-cells, thereby priming a robust anti-tumor immune response involving both CD4+ and CD8+ T-cells to control tumor progression.

Other names

ID8-DC vaccineID-8-DC vaccineID 8-DC vaccineID8-pulsed DC vaccineID-8-pulsed DC vaccineID 8-pulsed DC vaccineID8 lysate-loaded dendritic cell vaccineID-8 lysate-loaded dendritic cell vaccineID 8 lysate-loaded dendritic cell vaccineID8-pulsed DCID-8-pulsed DCID 8-pulsed DCOxidized ID8 lysate-pulsed dendritic cell vaccine